dimethyl 2-cyano-3-phenylpentanedioate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyl 2-cyano-3-phenylpentanedioate
• 化学式: C₁₄H₁₅NO₄
• 分子量: 261.277
• InChiKey: YVPGWPRLUIIMBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  76.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  dimethyl 2-cyano-3-phenylpentanedioate 在 sodium tetrahydroborate 、 cobalt(II) chloride 、 盐酸 、 水 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 methyl rel-(3R,4S)-6-oxo-4-phenylpiperidine-3-carboxylate
  参考文献：
  名称：

  EP2085383

  摘要：

  公开号：
• 作为产物：
  描述：

  氰乙酸甲酯 、 肉桂酸甲酯 在 sodium hydride 、 水 作用下， 以 甲醇 、 甲苯 、 水 为溶剂， 反应 15.5h， 生成 dimethyl 2-cyano-3-phenylpentanedioate
  参考文献：
  名称：

  EP2085383

  摘要：

  公开号：

文献信息

• An Unequivocal Synthesis of 4-Amino-1,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-2,7-diones and 2-Amino-3,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-4,7-diones
  作者：José I. Borrell、Jordi Teixidó、Blanca Martínez-Teipel、Blanca Serra、Josep Lluís Matallana、Marta Costa、Xavier Batllori

  DOI：10.1135/cccc19960901

  日期：——

  An unequivocal set of procedures for the synthesis of 4-amino-1,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-2,7-diones (7) and 2-amino-3,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-4,7-diones (8), in a maximum of four steps from an α,β-unsaturated ester 1, is reported. Thus, the acid hydrolysis of the 2,4-diaminopyrido[2,3-d]pyrimidines 3 yields the 4-amino-2-oxopyrido[2,3-d]pyrimidines 7 while the cyclization of the Michael adducts 9 (formed by reaction of 1 and methyl cyanoacetate) with guanidine affords the corresponding 2-amino-4-oxopyrido[2,3-d]pyrimidines 8. Both isomers were also obtained by hydrolysis of the 4-amino-2-bromo- and 2-amino-4-bromo-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-ones 5 and 6, respectively.

  一种无歧义的程序集，用于从α，β-不饱和酯1最多经过四个步骤合成4-氨基-1,5,6,8-四氢吡啶并[2,3-d]嘧啶-2,7-二酮（7）和2-氨基-3,5,6,8-四氢吡啶并[2,3-d]嘧啶-4,7-二酮（8）。因此，2,4-二氨基吡啶并[2,3-d]嘧啶3的酸水解产生4-氨基-2-氧代吡啶并[2,3-d]嘧啶7，而Michael加合物9（由1和氰乙酸甲酯反应形成）与胍嘧啶的环化则得到相应的2-氨基-4-氧代吡啶并[2,3-d]嘧啶8。这两种异构体也可通过4-氨基-2-溴和2-氨基-4-溴-5,6-二氢吡啶并[2,3-d]嘧啶-7(8H)-酮5和6的水解分别获得。
• PIPERIDINE DERIVATIVE OR SALT THEREOF
  申请人：Hachiya Shunichiro

  公开号：US20100029687A1

  公开（公告）日：2010-02-04

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  【问题】提供一种化合物，可用于治疗钙感受受体（CaSR）参与的疾病，特别是甲状旁腺功能亢进症。【解决方法】发现一种新的哌啶衍生物，其特征在于3位和4位中的一个位置被取代为含有芳基烷基等基团的氨甲基基团，另一个位置被取代为芳基、杂环芳基等，或其盐，具有出色的CaSR激动调节作用，并且具有出色的选择性，具有可能引起药物相互作用的CYP2D6抑制作用。基于以上发现，这种新的哌啶衍生物可用作治疗CaSR参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良、高钙血症等）的治疗剂。
• Piperidine derivative or salt thereof
  申请人：Astellas Pharma, Inc.

  公开号：US08153658B2

  公开（公告）日：2012-04-10

  To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  提供一种可以用于治疗钙感受受体（CaSR）参与的疾病，特别是甲状旁腺功能亢进症的化合物。发现一种新的哌啶衍生物，其特征在于3位和4位之一被取代为氨甲基基团，该氨甲基基团被取代为芳基烷基基团或类似物，另一位置被取代为芳基，杂环芳基或类似物，或其盐，具有出色的CaSR激动调节作用，并且具有出色的选择性，具有可能引起药物相互作用的CYP2D6抑制作用。基于以上发现，这种新的哌啶衍生物可用作治疗CaSR参与的疾病（甲状旁腺功能亢进症，肾性骨营养不良，高钙血症等）的治疗剂。
• PIPERIDINE DERIVATIVES OR SALTS THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2085383A1

  公开（公告）日：2009-08-05

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  [问题]提供一种可用于治疗钙传感受体（CaSR）参与的疾病，特别是甲状旁腺机能亢进的化合物。 [解决方法]发现一种新型哌啶衍生物，其特征在于 3 位和 4 位中的一个被氨甲基取代，另一个被芳基、杂芳基等取代，或其盐具有极好的 CaSR 激动调节作用，同时还具有极好的选择性，具有 CYP2D6 抑制作用，但有可能引起药物相互作用。基于以上所述，这种新型哌啶衍生物可作为治疗剂用于治疗 CaSR 参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良症、高钙血症等）。
• US8153658B2
  申请人：——

  公开号：US8153658B2

  公开（公告）日：2012-04-10